drugset / Trial / NCT02137564
Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma
Phase 2
Withdrawn
AIDS Malignancy Consortium
National Cancer Institute (NCI) · collabThe Emmes Company, LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies the effects, good and bad, of gamma secretase inhibitor PF-03084014 and to see how well it works in treating patients with acquired immune deficiency virus (AIDS)-associated Kaposi sarcoma. Gamma secretase inhibitor PF-03084014 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may shrink the tumor.
Timeline
- Start
- 2015-07
- Primary completion
- 2015-07
- Completion
- 2015-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nirogacestat | Small molecule | — | Oral |